|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||47.31 - 47.50|
|52-week range||47.31 - 47.50|
|Beta (5Y monthly)||1.62|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year. Shares down.
Image source: The Motley Fool. Agios Pharmaceuticals Inc (NASDAQ: AGIO)Q4 2020 Earnings CallFeb 25, 2021, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, and welcome to Agios' Fourth Quarter 2020 Conference Call.
The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...